Literature DB >> 31755070

The Evolving Role of Thiopurines in Inflammatory Bowel Disease.

Saurabh Kapur1, Stephen B Hanauer2.   

Abstract

PURPOSE OF REVIEW: With the advent of biologic therapies for the treatment of IBD, the roles of thiopurines have continued to evolve. This review will focus on recent advances in pharmacology and the safety and efficacy of thiopurines as maintenance therapies for steroid-induced remissions, post-surgical maintenance of remission, and as combination therapies to reduce immunogenicities of biologic agents. RECENT
FINDINGS: Due to pharmacogenetics of TPMT, thiopurine dosing is more effectively based on monitoring of thiopurine metabolites rather than weight-based dosing. Thiopurines continue to have a role as maintenance therapy after steroid-induced remissions and in combination with biologics to induce and maintain remission. Safety monitoring includes measurements of blood counts, liver chemistries, as well as dermatologic evaluations and protection from sun exposure. Thiopurines appear to be safe during pregnancies and while very uncommon, lymphomas (including hepatosplenic T cell lymphomas) remain a recognized risk, particularly in younger and older males.

Entities:  

Keywords:  Immunogenicity; Inflammatory bowel disease; Steroid-induced remission; Steroids; TPMT; Thiopurines

Year:  2019        PMID: 31755070     DOI: 10.1007/s11938-019-00249-y

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  107 in total

1.  Colorectal Cancer in Inflammatory Bowel Diseases: A Population-Based Study in Utah.

Authors:  N Jewel Samadder; John F Valentine; Stephen Guthery; Harminder Singh; Charles N Bernstein; Yuan Wan; Jathine Wong; Kenneth Boucher; Lisa Pappas; Kerry Rowe; Mary Bronner; Cornelia M Ulrich; Randall W Burt; Karen Curtin; Ken R Smith
Journal:  Dig Dis Sci       Date:  2017-01-03       Impact factor: 3.199

2.  Azathioprine is essential following cyclosporine for patients with steroid-refractory ulcerative colitis.

Authors:  Nobuyuki Miyake; Takafumi Ando; Kazuhiro Ishiguro; Osamu Maeda; Osamu Watanabe; Yutaka Hirayama; Keiko Maeda; Kazuhiro Morise; Masanobu Matsushita; Kazuhiro Furukawa; Kohei Funasaka; Masanao Nakamura; Ryoji Miyahara; Naoki Ohmiya; Hidemi Goto
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

3.  Hemophagocytic lymphohistiocytosis caused by primary Epstein-Barr virus in patient with Crohn's disease.

Authors:  Francesco Virdis; Sara Tacci; Federico Messina; Massimo Varcada
Journal:  World J Gastrointest Surg       Date:  2013-11-27

4.  The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery.

Authors:  Pavol Papay; Walter Reinisch; Elien Ho; Cornelia Gratzer; Donata Lissner; Harald Herkner; Stefan Riss; Clemens Dejaco; Wolfgang Miehsler; Harald Vogelsang; Gottfried Novacek
Journal:  Am J Gastroenterol       Date:  2009-12-15       Impact factor: 10.864

5.  Vedolizumab as induction and maintenance therapy for Crohn's disease.

Authors:  William J Sandborn; Brian G Feagan; Paul Rutgeerts; Stephen Hanauer; Jean-Frédéric Colombel; Bruce E Sands; Milan Lukas; Richard N Fedorak; Scott Lee; Brian Bressler; Irving Fox; Maria Rosario; Serap Sankoh; Jing Xu; Kristin Stephens; Catherine Milch; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

6.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

7.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Authors:  Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

Review 8.  Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews.

Authors:  Brian G Feagan; Nilesh Chande; John K MacDonald
Journal:  Inflamm Bowel Dis       Date:  2013-08       Impact factor: 5.325

Review 9.  Reduced Risk of Inflammatory Bowel Disease-associated Colorectal Neoplasia with Use of Thiopurines: a Systematic Review and Meta-analysis.

Authors:  Zhehui Zhu; Zubing Mei; Yuegui Guo; Guanghui Wang; Tingyu Wu; Ximao Cui; Zhenyu Huang; Yilian Zhu; Dongpeng Wen; Jinglve Song; Hailan He; Weimin Xu; Long Cui; Chenying Liu
Journal:  J Crohns Colitis       Date:  2018-04-27       Impact factor: 9.071

10.  Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.

Authors:  Magali Lemaitre; Julien Kirchgesner; Annie Rudnichi; Fabrice Carrat; Mahmoud Zureik; Franck Carbonnel; Rosemary Dray-Spira
Journal:  JAMA       Date:  2017-11-07       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.